Literature DB >> 27504063

Pharmaceutical Approval Update.

Michele B Kaufman.   

Abstract

Venetoclax (Venclexta) for chronic lymphocytic leukemia; riboflavin 5'-phosphate solutions (Photrexa Viscous and Photrexa) for progressive keratoconus; and pimavanserin (Nuplazid) for Parkinson's disease psychosis.

Entities:  

Year:  2016        PMID： 27504063      PMCID： PMC4959615     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  1 in total

Review 1.  Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.

Authors:  Brianna L Combs; Arthur G Cox
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-08       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.